Hofseth Biocare (HBC)

[TekBot]

NOTIFICATION OF MAJOR SHAREHOLDINGS

Reference is made to the stock exchange announcement from Hofseth BioCare ASA on
3 July 2026 and today, 6 August 2026, where the share capital increase from the
issuance of the offer shares in tranche 2 has been registered with the Norwegian
…

Vis børsmeldingen

Register of Business Enterprises.

Following the share capital increase, Research Corporation Pty Ltd., which holds
a total of 24,280,748 ordinary shares in HBC, falls under the 5 percent
threshold and now represent 4.80 % of the voting rights in HBC.

Kilde

[TekBot]

Notification of Major Holdings

IFM Independent Fund Management AG, are a Liechtenstein-based fund management
company acting as trustee for the following three investment funds:

…

Vis børsmeldingen

• Bonafide Global Fish Fund
• Bonafide Investment Fund - HBC II

According to the information published on the website of the Oslo Stock
Exchange, the total number of outstanding ordinary shares of Hofseth Biocare ASA
currently amounts to 506,235,638. Based on this figure, IFM Independent Fund
Management AG will hold a total of 9.59% of the voting rights in Hofseth Biocare
ASA as of August 06, 2026.

Please find attached the ESMA standard form for the notification of major
holdings.

Kilde

[TekBot]

Hofseth BioCare ASA: SECOND QUARTER 2026 FINANCIAL REPORT

HBC recorded total operating revenues of NOK 65.7 million in the second quarter
of 2026, compared to NOK 68.4 million in the same period last year. Net
operating revenues were NOK 63.1 million, down from NOK 67.8 million in Q2
…

Vis børsmeldingen

2025. EBITDA for the quarter was negative NOK 2.7 million, compared to negative
      NOK 5.4 million in Q2 2025. The Operational EBITDA* amounted to negative NOK
      0.6 million (positive NOK 1.3 million in Q2 2025), excluding non-recurring and
      strategic development costs such as clinical trials and R&D expenses, and Berkåk
      project costs. The operating result (EBIT) was negative NOK 12.9 (-14.9) in the
      last quarter. Cash and cash equivalents increased by NOK 59.7 million during the
      quarter, ending at NOK 108.0 million as of 30 June 2026 (68.0). Including
      available credit facilities, total liquidity was NOK 109.0 million at quarter-
      end (76.5).

Highlights in the second quarter:

• Total operating revenue of NOK 65.7 million (68.4), achieved with
  approximately 44 per cent less raw material processed than in Q2 2025. Gross
  margin rose to 50.0 per cent, from 43.5 per cent in Q1 2026.
• Contracts agreed and renewed during the quarter reflect year-on-year
  increases of more than 100 per cent in the average selling price of both
  ProGo® bioactive peptides and OmeGo® Full Spectrum Omegas, supported by
  tight global marine protein and fish oil markets.
• B2B Consumer Health revenue grew 72 per cent quarter-on-quarter to NOK 16.0
  million. A global exclusive agreement was signed for ProGo® in network
  marketing channels, and the first product was launched during the quarter.
• The Brilliant™ retail footprint is expanding to more than 20 territories,
  with new agreements reached or close to conclusion with major retailers in
  Australia, Japan and the UAE. The Cardio™ softgel range for Boots UK is
  progressing following the first orders received in Q1.
• On 28 June 2026 the Board completed a private placement generating gross
  proceeds of NOK 144.5 million, of which NOK 73.2 million through conversion
  of receivables. The placement settles in two tranches across Q2 and Q3 2026.
• At AecorBio, the MA-022s asthma programme completed two preclinical studies
  with results submitted for peer-reviewed publication, and FT-002a-O advanced
  toward an FDA IND submission targeted for late 2026. Recruitment in the NT-
  II™ knee-pain trial remains on track, with results expected in H2 2026.

Please find the HBC Q2 2026 Financial report attached.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

About Hofseth BioCare ASA:
Hofseth BioCare is a Norwegian consumer and pet health company founded on the
core values of sustainability, optimal utilization of natural resources and full
traceability. It upcycles the side streams of the salmon industry, taking fresh
filleted salmon and converting it from a waste product into ingredients to
improve human and pet health. These ingredients are ProGo®, a mix of bioactive
peptides and collagen; OmeGo®, a whole salmon oil containing all the fatty acid
fractions found in fish; and CalGo®/NT-II® salmon bone powder containing calcium
hydroxyapatite and undenatured collagen for bone and joint health.

HBC places scientific evidence at the forefront, which has led to important
academic partnerships and the identification of unique health benefits. HBC is
listed on Oslo Stock Exchange with ticker “HBC”.

*) Alternative Performance Measures are further described on p. 13 in the
financial report.

This information is subject to the disclosure requirements pursuant to
Section 5-12 of the Norwegian Securities Trading Act

Kilde

[TekBot]

HOFSETH BIOCARE ASA: MANAGEMENT CHANGE

Hofseth BioCare ASA (“HBC” or the “Company”) today announces the appointment of
Leif Arne Giske as new Chief Financial Officer (CFO) of the HBC Group, effective
immediately.
…

Vis børsmeldingen

Mr. Giske has been with Hofseth BioCare since 2013 and previously held the
position of Group Accounting Manager. Through this role he has had overall
responsibility for the Group’s accounting, financial reporting and control
functions.

Mr. Giske holds 3,339,384 shares in HBC and will be part of the Company’s
executive management team.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

About Hofseth BioCare ASA:

Hofseth BioCare is a Norwegian consumer and pet health company founded on the
core values of sustainability, optimal utilization of natural resources and full
traceability. It upcycles the side streams of the salmon industry, taking fresh
filleted salmon and converting it from a waste product into ingredients to
improve human and pet health. These ingredients are ProGo®, a mix of bioactive
peptides and collagen; OmeGo®, a whole salmon oil containing all the fatty acid
fractions found in fish; and CalGo®/NT-II® salmon bone powder containing calcium
hydroxyapatite and undenatured collagen for bone and joint health. HBC places
scientific evidence at the forefront, which has led to important academic
partnerships and the identification of unique health benefits. HBC is listed on
Oslo Stock Exchange with ticker “HBC”.

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION

Christoph Baldegger, primary insider and member of the Board of Directors in
Hofseth BioCare ASA (“HBC”) has today, 17 September 2026, bought 2,500,000
shares in HBC in an off-market transaction at an average price of NOK 1.13 per
…

Vis børsmeldingen

share.

After the transaction, Mr. Baldegger holds 8,824,899 shares in HBC, equal to
approximately 1.86 % of the total outstanding A-shares with voting rights.

For further information, contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966 E-mail: joo@hofsethbiocare.no
(mailto:joo@hofsethbiocare.no)

This information is subject to the disclosure requirements in the Market Abuse
Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading
Act section 5-12.

Kilde